Literature DB >> 24715748

Conjugated estrogens and bazedoxifene.

Dennis J Cada1, Danial E Baker2.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The March 2014 monograph topics are umeclidinium and vilanterol inhalation powder, sucroferric oxyhydroxide, luliconazole, edoxaban, and secukinumab. The DUE/MUE is on fentanyl transdermal system.

Entities:  

Year:  2014        PMID: 24715748      PMCID: PMC3971114          DOI: 10.1310/hpj4903-273

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  23 in total

1.  Efficacy and safety of bazedoxifene in postmenopausal Asian women.

Authors:  L Xu; K-S Tsai; G S Kim; Y Wu; P Vincendon; A A Chines; G D Constantine
Journal:  Osteoporos Int       Date:  2010-06-10       Impact factor: 4.507

2.  Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial.

Authors:  T J de Villiers; A A Chines; S Palacios; P Lips; A Z Sawicki; A B Levine; C Codreanu; N Kelepouris; J P Brown
Journal:  Osteoporos Int       Date:  2010-06-10       Impact factor: 4.507

3.  Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity.

Authors:  Barry S Komm; Yogendra P Kharode; Peter V N Bodine; Heather A Harris; Chris P Miller; C Richard Lyttle
Journal:  Endocrinology       Date:  2005-06-16       Impact factor: 4.736

4.  Breast density changes in a randomized controlled trial evaluating bazedoxifene/conjugated estrogens.

Authors:  Jennifer A Harvey; JoAnn V Pinkerton; Edmund C Baracat; Harry Shi; Arkadi A Chines; Sebastian Mirkin
Journal:  Menopause       Date:  2013-02       Impact factor: 2.953

5.  Effects of bazedoxifene on bone mineral density, bone turnover, and safety in postmenopausal Japanese women with osteoporosis.

Authors:  Akira Itabashi; Kousei Yoh; Arkadi A Chines; Takami Miki; Masahiko Takada; Hiroshi Sato; Itsuo Gorai; Toshitsugu Sugimoto; Hideki Mizunuma; Hiroshi Ochi; Ginger D Constantine; Hiroaki Ohta
Journal:  J Bone Miner Res       Date:  2011-03       Impact factor: 6.741

6.  Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.

Authors:  Paul D Miller; Arkadi A Chines; Claus Christiansen; Hans C Hoeck; David L Kendler; E Michael Lewiecki; Grattan Woodson; Amy B Levine; Ginger Constantine; Pierre D Delmas
Journal:  J Bone Miner Res       Date:  2008-04       Impact factor: 6.741

7.  Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women.

Authors:  David F Archer; Vivian Lewis; Bruce R Carr; Sophie Olivier; James H Pickar
Journal:  Fertil Steril       Date:  2009-07-26       Impact factor: 7.329

8.  Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women.

Authors:  Wulf Utian; Holly Yu; Joel Bobula; Sebastian Mirkin; Sophie Olivier; James H Pickar
Journal:  Maturitas       Date:  2009-07-31       Impact factor: 4.342

9.  Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis.

Authors:  JoAnn V Pinkerton; David F Archer; Wulf H Utian; José C Menegoci; Amy B Levine; Arkadi A Chines; Ginger D Constantine
Journal:  Menopause       Date:  2009 Nov-Dec       Impact factor: 2.953

10.  Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis.

Authors:  Claus Christiansen; Charles H Chesnut; Jonathan D Adachi; Jacques P Brown; César E Fernandes; Annie Wc Kung; Santiago Palacios; Amy B Levine; Arkadi A Chines; Ginger D Constantine
Journal:  BMC Musculoskelet Disord       Date:  2010-06-22       Impact factor: 2.362

View more
  1 in total

1.  Long-Term Administration of Conjugated Estrogen and Bazedoxifene Decreased Murine Fecal β-Glucuronidase Activity Without Impacting Overall Microbiome Community.

Authors:  Karen Lee Ann Chen; Xiaoji Liu; Yiru Chen Zhao; Kadriye Hieronymi; Gianluigi Rossi; Loretta Sue Auvil; Michael Welge; Colleen Bushell; Rebecca Lee Smith; Kathryn E Carlson; Sung Hoon Kim; John A Katzenellenbogen; Michael Joseph Miller; Zeynep Madak-Erdogan
Journal:  Sci Rep       Date:  2018-05-25       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.